GlobeNewswire by notified

Ultimovacs Expands High Dose Cohort Size in TENDU Phase I Prostate Cancer Trial after Safety Review

Share
  • The TENDU interim safety results from nine patients show no safety concerns
  • Trial extended to enroll up to three additional patients at the highest dose level
  • TENDU designed to evaluate the Tetanus-Epitope Targeting (TET)-platform in patients with prostate cancer

Oslo, 18August 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, has completed treatment of three patients at the highest dose cohort in the phase I TENDU trial without any safety concerns. Based on these results, the company plans to enroll up to three additional patients at the highest dose level.

The Drug Safety Monitoring Board, a group of experts set up to monitor patient safety during a clinical trial, found no safety concerns in any of the three dose cohorts. A total of nine patients have now been treated; three at each dose level (40 mcg, 400 mcg and 960 mcg). Ultimovacs plans to enroll up to three additional patients at the highest dose level (960 mcg) providing a broader base of early safety data for the TET platform.

“We are very encouraged by the continuing progress of the phase I safety evaluation of the TET platform. With no safety concerns at any dose, we have decided to enroll up to three additional patients at the highest dose level, providing extended data from TENDU on the safety and tolerability of TET for prostate cancer patients.” said Jens Bjørheim, Chief Medical Officer of Ultimovacs. “The data from TENDU, in turn, may provide insights that are useful in Ultimovacs’ broader plans for the development of the TET platform.”

The TET platform, an innovative adjuvant technology, allows for the design and production of multiple therapeutic cancer vaccines. It can potentially be used to strengthen and increase T cell responses to cancer cells by targeting antigens that are specific to one type of cancer or common to many tumor types. The vaccine used in the TENDU study contains prostate cancer-specific antigens. By combining cancer antigens and the vaccine adjuvant in the same molecule, the TET platform can generate vaccine candidates with a potential beneficial safety and administration profile, including presenting an opportunity to treat patients at an earlier stage of their disease.

The TENDU study is a first-in-human, dose-escalation study designed to generate initial safety and immune activation data. This study is investigating a prostate cancer-specific therapeutic TET-based vaccine in patients who have relapsed following radical prostatectomy.

==ENDS==

About the TET-platform
All vaccines consist of two components, adjuvant and antigen. The adjuvant activates the immune system so that a relevant immune response can occur. The antigen directs the quality of the immune response. Together the adjuvant and the antigen ensure a specific and effective immune response.

The Tetanus-Epitope Targeting (TET)-platform offers an approach to strengthen and increase T cell responses against cancer-specific peptides by combining cancer-specific antigens and vaccine adjuvant in the same conjugated molecule, allowing for a beneficial safety profile and simplifying administration. The platform generates new, first-in-class cancer vaccine candidates that harness pre-existing antibody responses resulting from standard tetanus vaccinations. TET vaccine candidates can be tailored to many types of cancer, and to infectious diseases.

About TENDU
The TENDU clinical trial (NCT04701021) is a first-in-human, phase I study and the first clinical trial of a vaccine from Ultimovacs' Tetanus-Epitope Targeting (TET)-platform. The trial is being conducted at the Oslo University Hospital, Norway, and evaluates the safety of the vaccine in prostate cancer patients who have relapsed after radical prostatectomy. The primary objective of the study is to evaluate the safety and tolerability of three different doses of the vaccine. Patients will receive the vaccine prior to obtaining standard-of-care treatment consisting of radiation and antihormone therapy and will be followed for 6 months after the last dose of the vaccine to assess immunological responses such as the activation of T cells and anti-tumor activity.

About Ultimovacs
Ultimovacs is an immunotherapy company developing immune-stimulatory vaccines to treat a broad range of cancers. Ultimovacs’ lead universal cancer vaccine candidate UV1 targets human telomerase (hTERT), present in 85-90% of cancers in all stages of tumor growth. By directing the immune system to hTERT antigens, UV1 drives CD4 helper T cells to the tumor to activate an immune system cascade and increase anti-tumor responses. With a broad phase II program in five cancer indications enrolling more than 650 patients, Ultimovacs aims to clinically demonstrate UV1’s impact in multiple cancer types, in combination with other immunotherapies, for patients with unmet needs. Ultimovacs’ second technology approach, based on the proprietary Tetanus-Epitope-Targeting (TET) platform, combines tumor-specific peptides and adjuvant in the same molecule and entered phase I studies in 2021.

For further information, please see www.ultimovacs.com or contact:

Carlos de Sousa, CEO
Email: carlos.desousa@ultimovacs.com
Phone: +47 908 92507

Anne Worsøe, Head of IR & Communication
Email: anne.worsoe@ultimovacs.com
Phone: +47 90686815

Mary-Ann Chang, LifeSci Advisors
Email: mchang@lifesciadvisors.com
Phone: +44 7483 284 853

This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5-12 in the Norwegian Securities Trading Act.

This stock exchange announcement was published by Joachim Midttun, Finance Manager at Ultimovacs ASA, on 18August, 2022 at 08:00 CET.


To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Aduro Announces Readiness of Scaled-up Continuous Flow Plastic Reactor for Customer Trials6.10.2022 13:00:00 CEST | Press release

SARNIA, Ontario, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc. (“Aduro” or the “Company”) (CSE: ACT) (OTCQB: ACTHF) (FSE: 9D50), a Canadian developer of patented water-based technologies to chemically recycle plastics and transform heavy crude and renewable oils into new-era resources and higher-value fuels, announces it is entering final stages of completion of its pilot-scale HydrochemolyticTM continuous flow plastic (“R2 Plastic”) reactor. The R2 Plastic unit is in the final assembly phase, plans for testing, commissioning, and certification are finalised and expected to be complete by mid November 2022. The R2 Plastic unit is the Company’s customer engagement unit and is designed to handle various plastic feedstocks such as polyethylene, polypropylene, and polystyrene as single stream materials, followed by a mixture of these feedstock streams. The R2 Plastic will also be used to evaluate the impact of materials found in multilayer plastics, such as paper, paper b

Nexstim NBS 5+ System Continues to Generate Interest in the US6.10.2022 11:00:00 CEST | Press release

Press release,Helsinki,6October2022 at12PM (EEST) Nexstim NBS 5+ System Continues to Generate Interest in the US Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that Drs. Lauren Marangell and Rayan Al Jurdi, experts in the treatment of major depression, have purchased a NBS 5+ system. Marangell and Al Jurdi, both previously faculty at Baylor College of Medicine, founded Brain Health Consultants and TMS Center as a private outpatient program offering state of the art treatment for people with depression and related disorders. The NBS 5+ system, released in the United States in 2021, combines the capabilities of Nexstim’s NBS and NBT® systems. It thus enables the delivery of both diagnostic and therapeutic applications; diagnostic use meaning identifying the precise location and amount of stimulation required to active specific nerve cells for use across specialities such as neurosurgery, neuroradiology and psychiatry and therapeutic use referring to the treatment o

Huhtamaki publishes its Q3 2022 Interim Report on October 21, 20226.10.2022 09:00:00 CEST | Press release

HUHTAMÄKI OYJ PRESS RELEASE 6.10.2022 AT 10:00 Huhtamaki publishes its Q3 2022 Interim Report on October 21, 2022 Huhtamäki Oyj will publish its Q3 2022 Interim Report on Friday, October 21, 2022, approximately at 8:30 Finnish time (EEST). The release and related results presentation material will be available after publishing at www.huhtamaki.com/investors. Teleconference Huhtamaki will arrange a combined webcast and teleconference on the same day at 9:30 Finnish time. Huhtamaki´s President and CEO Charles Héaulmé and CFO Thomas Geust will present the results. The event will be followed by a Q&A session. The event will be held in English, it can be followed real-time at: https://huhtamaki.videosync.fi/2022-q3-results/ If you wish to ask questions, please dial one of the following numbers 5-10 minutes prior to the call start: Finland: +358 9 2319 5436 Sweden: +46 (0) 8 5051 0086 UK: +44 (0) 33 0551 0211 US: +1 646 843 4609 Participant Passcode: 0422950# An on-demand replay of the audio

Yara calls for urgent action to reduce Europe’s food dependency on Russia6.10.2022 08:31:11 CEST | Press release

Oslo, October 6, 2022: Yara calls on the European Union and national governments to act urgently and decisively to ensure Europe reduces, and not strengthens, its dependency on Russia for food and fertilizers. A strong European fertilizer industry is crucial not only for ensuring food security in Europe and globally but also for ensuring that Europe can continue to take the lead in the green transition. “It is imperative that the war on Ukraine does not destroy the work towards a net-zero future. It is unthinkable that we will reach the climate targets without a strong, green European industry. Instead of weakening the position of the European fertilizer industry, which is a frontrunner in decarbonization, we need massive, coordinated efforts to reach zero emissions, while at the same time reducing our dependencies on Russia,” says Svein Tore Holsether, President and Chief Executive Officer of Yara. Curtailed production in Europe reduces worldwide availability of fertilizers and has di

Chief Legal Officer Nassib Abou-Khalil to leave Nokia6.10.2022 08:00:00 CEST | Press release

Nokia Corporation Stock Exchange Release 6 October 2022 at 9:00 EEST Chief Legal Officer Nassib Abou-Khalil to leave Nokia Espoo, Finland – Nokia’s Chief Legal Officer, Nassib Abou-Khalil, has decided to leave Nokia and step down from its Group Leadership Team. A recruitment process will begin immediately for his successor. Nassib Abou-Khalil joined Nokia in 2014 and was appointed Chief Legal Officer in 2019. Before that role, he held various legal and compliance leadership positions in the company, including working as the general counsel for customer operations and leading the integration of the compliance programs of Alcatel-Lucent and Nokia. “This was a very difficult decision for me. However, after eight years with the company, it’s time for personal renewal and seeking new challenges externally. Whatever I have been able to realize – both as Nokia’s CLO and in our industry-leading inclusion and diversity work – has been possible only because of the support and encouragement I hav